Safety and Efficacy of MesenchymalStromalCells Derived from Adipose Tissue of Non-related Donors in Patients with The Butterfly Disease: Clinical Trial Phase I/II Safety and Efficacy of MesenchymalStromalCellsDerived from Adipose Tissue of Non-related Donors in ...
Safety and Efficacy of Allogenic Adipose Tissue-derived MesenchymalStromalCells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II - MSC-EB Safety and Efficacy of AllogenicAdipose Tissue-derived MesenchymalStromalCellsin Patients with Epi ...
Epidermolysis bullosa congenita;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Epidermolysis bullosa congenita;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonata ...
Product Name: allogeneic adipose tissue-derived MSC INN or Proposed INN: Human allogeneic adipose tissue-derived mesenchymal stem cells expanded Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED Product Name: allogeneic adipose tissue-derived MSC INN or Proposed INN: Human allogeneic adipose tis ...
A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis ...
A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. - A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients. A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis ...
dystrophic epidermolysis bullosa
ISN001, the sheet containing allogenic adipose derived mesenchymalstromalcells (1000000/sheet), is applied to the lesion(s) once a week up to 8 times ISN001, the sheet containing allogenicadipose derived mesenchymalstromalcells(1000000/sheet), is a ...
A prospective phase I/II study to evaluate allogeneic mesenchymalstromalcells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. A prospective phase I/II study to evaluate allogeneic mesenchymalstromalcellsfor the treatment of ...
A prospective phase I/II study to evaluate allogeneic mesenchymalstromalcells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa. - EBSTEM A prospective phase I/II study to evaluate allogeneic mesenchymalstromalcellsfor the treatment of ...